Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL by Chelsea C. Pinnix, Andrea K. Ng, Bouthaina S.

Slides:

Advertisements

Similar presentations

Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.

Advertisements

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas,

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.

Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment.

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

How I treat extramedullary myeloma

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Alternate designs for conduct and analysis of phase I cancer trials

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

by Alexander Röth, Andreas Hüttmann, Russell P

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,

Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation by.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

Volume 2(Supplement 1):8-10

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Impact of Pretransplantation 18F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell–Depleted Allogeneic Transplantation.

Biology of Blood and Marrow Transplantation

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Volume 2(Supplement 1):46-49

by Michael R. DeBaun, and Ellen Wright Clayton

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Impact of age on clinical risk scores in follicular lymphoma

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL by Chelsea C. Pinnix, Andrea K. Ng, Bouthaina S. Dabaja, Sarah A. Milgrom, Jillian R. Gunther, C. David Fuller, Grace L. Smith, Zeinab Abou Yehia, Wei Qiao, Christine F. Wogan, Mani Akhtari, Osama Mawlawi, L. Jeffrey Medeiros, Hubert H. Chuang, William Martin-Doyle, Philippe Armand, Ann S. LaCasce, Yasuhiro Oki, Michelle Fanale, Jason Westin, Sattva Neelapu, and Loretta Nastoupil BloodAdv Volume 2(11):1334-1343 June 12, 2018 © 2018 by The American Society of Hematology

Chelsea C. Pinnix et al. Blood Adv 2018;2:1334-1343 © 2018 by The American Society of Hematology

Survival outcomes after DA-R-EPOCH for PMBCL Survival outcomes after DA-R-EPOCH for PMBCL. PFS (A) and OS (B) after treatment with DA-R-EPOCH among patients with PMBCL treated at 2 tertiary cancer centers (cohorts 1 and 2). Survival outcomes after DA-R-EPOCH for PMBCL. PFS (A) and OS (B) after treatment with DA-R-EPOCH among patients with PMBCL treated at 2 tertiary cancer centers (cohorts 1 and 2). Chelsea C. Pinnix et al. Blood Adv 2018;2:1334-1343 © 2018 by The American Society of Hematology

Effect of pretreatment and posttreatment radiographic parameters on PFS. Elevated pretreatment MTV (A) and TLG (B) were associated with inferior PFS. Posttherapy increased CT residual mass volume (C), SUVmax (D), and end-of-therapy Deauville score (E-F) predicted inferior PFS. The combination of pretreatment TLG and posttreatment Deauville score (G-H) were also associated with decreased PFS. Effect of pretreatment and posttreatment radiographic parameters on PFS. Elevated pretreatment MTV (A) and TLG (B) were associated with inferior PFS. Posttherapy increased CT residual mass volume (C), SUVmax (D), and end-of-therapy Deauville score (E-F) predicted inferior PFS. The combination of pretreatment TLG and posttreatment Deauville score (G-H) were also associated with decreased PFS. Chelsea C. Pinnix et al. Blood Adv 2018;2:1334-1343 © 2018 by The American Society of Hematology